Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Trump Says Anthropic No Longer Seen as National Security Threat 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
TUSTIN, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred Stock is payable on January 4, 2016 to holders of record at the close of business on December 18, 2015.
The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from October 1, 2015 through December 31, 2015. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "PPHMP".
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of previously treated non-small cell lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Contacts: Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 [email protected] Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
